Cancer Research Annual Meeting 2010  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 9417, October 1, 2007. doi: 10.1158/0008-5472.CAN-07-1286
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loberg, R. D.
Right arrow Articles by Pienta, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loberg, R. D.
Right arrow Articles by Pienta, K. J.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo

Robert D. Loberg1,2, Chi Ying2, Matt Craig2, Lashon L. Day1, Erin Sargent1, Chris Neeley2, Kirk Wojno2, Linda A. Snyder4, Li Yan3 and Kenneth J. Pienta1,2

1 Department of Urology, University of Michigan Urology Center and 2 Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; and 3 Department of Hematology/Oncology and 4 Oncology Research, Centocor, Inc., Malvern, Pennsylvania

Requests for reprints: Robert D. Loberg, University of Michigan, 7312 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0946. Phone: 734-647-3421; Fax: 734-647-9480; E-mail: rloberg{at}umich.edu.

The identification of novel tumor-interactive chemokines and the associated insights into the molecular and cellular basis of tumor-microenvironment interactions have continued to stimulate the development of targeted cancer therapeutics. Recently, we have identified monocyte chemoattractant protein 1 (MCP-1; CCL2) as a prominent regulator of prostate cancer growth and metastasis. Using neutralizing antibodies to human CCL2 (CNTO888) and the mouse homologue CCL2/JE (C1142), we show that treatment with anti-CCL2/JE antibody (2 mg/kg, twice weekly i.p.) attenuated PC-3Luc–mediated overall tumor burden in our in vivo model of prostate cancer metastasis by 96% at 5 weeks postintracardiac injection. Anti-CCL2 inhibition was not as effective as docetaxel (40 mg/kg, every week for 3 weeks) as a single agent, but inhibition of CCL2 in combination with docetaxel significantly reduced overall tumor burden compared with docetaxel alone, and induced tumor regression relative to initial tumor burden. These data suggest an interaction between tumor-derived chemokines and host-derived chemokines acting in cooperation to promote tumor cell survival, proliferation, and metastasis. [Cancer Res 2007;67(19):9417–24]




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
G. Solinas, G. Germano, A. Mantovani, and P. Allavena
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
J. Leukoc. Biol., November 1, 2009; 86(5): 1065 - 1073.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Lu and Y. Kang
Chemokine (C-C Motif) Ligand 2 Engages CCR2+ Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone
J. Biol. Chem., October 16, 2009; 284(42): 29087 - 29096.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. K. Popivanova, F. I. Kostadinova, K. Furuichi, M. M. Shamekh, T. Kondo, T. Wada, K. Egashira, and N. Mukaida
Blockade of a Chemokine, CCL2, Reduces Chronic Colitis-Associated Carcinogenesis in Mice
Cancer Res., October 1, 2009; 69(19): 7884 - 7892.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Hu, L. Sun, C. Guo, Q. Liu, Z. Zhou, L. Peng, J. Pan, L. Yu, J. Lou, Z. Yang, et al.
Tumor Cell-Microenvironment Interaction Models Coupled with Clinical Validation Reveal CCL2 and SNCG as Two Predictors of Colorectal Cancer Hepatic Metastasis
Clin. Cancer Res., September 1, 2009; 15(17): 5485 - 5493.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
R. L. GIUNTOLI II, T. J. WEBB, A. ZOSO, O. ROGERS, T. P. DIAZ-MONTES, R. E. BRISTOW, and M. OELKE
Ovarian Cancer-associated Ascites Demonstrates Altered Immune Environment: Implications for Antitumor Immunity
Anticancer Res, August 1, 2009; 29(8): 2875 - 2884.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
K. MIZUTANI, H. ROCA, Z. VARSOS, and K. J. PIENTA
Possible Mechanism of CCL2-induced Akt Activation in Prostate Cancer Cells
Anticancer Res, August 1, 2009; 29(8): 3109 - 3113.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Carcinogenesis, July 1, 2009; 30(7): 1073 - 1081.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Izhak, G. Wildbaum, Y. Zohar, R. Anunu, L. Klapper, A. Elkeles, J. Seagal, E. Yefenof, M. Ayalon-Soffer, and N. Karin
A Novel Recombinant Fusion Protein Encoding a 20-Amino Acid Residue of the Third Extracellular (E3) Domain of CCR2 Neutralizes the Biological Activity of CCL2
J. Immunol., July 1, 2009; 183(1): 732 - 739.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
A. Mantovani
Chemokines as a Key Component of Cancer-Related Inflammation
Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 9 - 13.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Khatri, Y. Husaini, K. Ow, J. Chapman, and P. J. Russell
Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines
Clin. Cancer Res., April 1, 2009; 15(7): 2323 - 2334.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
G. T. Stathopoulos, I. Psallidas, A. Moustaki, C. Moschos, A. Kollintza, S. Karabela, I. Porfyridis, S. Vassiliou, M. Karatza, Z. Zhou, et al.
A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion
J Natl Cancer Inst, October 15, 2008; 100(20): 1464 - 1476.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Roca, Z. Varsos, and K. J. Pienta
CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation
J. Biol. Chem., September 5, 2008; 283(36): 25057 - 25073.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.